Follow
Dr Subhajit Biswas
Dr Subhajit Biswas
Verified email at iicb.res.in - Homepage
Title
Cited by
Cited by
Year
Occult hepatitis B infection in blood donors from South East Asia: molecular characterisation and potential mechanisms of occurrence
D Candotti, CK Lin, D Belkhiri, T Sakuldamrongpanich, S Biswas, S Lin, ...
Gut 61 (12), 1744-1753, 2012
1352012
In vitro probiotic characterization of Lactobacillus casei isolated from marine samples
P Das, S Khowala, S Biswas
Lwt 73, 383-390, 2016
892016
Antiviral drug resistance and helicase–primase inhibitors of herpes simplex virus
HJ Field, S Biswas
Drug Resistance Updates 14 (1), 45-51, 2011
782011
Specific amino acid substitutions in the S protein prevent its excretion in vitro and may contribute to occult hepatitis B virus infection
S Biswas, D Candotti, JP Allain
Journal of Virology 87 (14), 7882-7892, 2013
662013
The helicase primase inhibitor, BAY 57-1293 shows potent therapeutic antiviral activity superior to famciclovir in BALB/c mice infected with herpes simplex virus type 1
S Biswas, L Jennens, HJ Field
Antiviral research 75 (1), 30-35, 2007
632007
Herpesvirus latency and therapy—from a veterinary perspective
HJ Field, S Biswas, IT Mohammad
Antiviral research 71 (2-3), 127-133, 2006
522006
Herpes Simplex Virus Helicase—Primase Inhibitors: Recent Findings from the Study of Drug Resistance Mutations
S Biswas, HJ Field
Antiviral Chemistry and Chemotherapy 19 (1), 1-6, 2008
472008
Computational modelling supports that dengue virus envelope antibodies can bind to SARS-CoV-2 receptor binding sites: Is pre-exposure to dengue virus protective against COVID …
H Nath, A Mallick, S Roy, S Sukla, S Biswas
Computational and Structural Biotechnology Journal 19, 459-466, 2021
442021
A single drug-resistance mutation in HSV-1 UL52 primase points to a difference between two helicase–primase inhibitors in their mode of interaction with the antiviral target
S Biswas, G Kleymann, M Swift, LS Tiley, J Lyall, J Aguirre-Hernandez, ...
Journal of antimicrobial chemotherapy 61 (5), 1044-1047, 2008
432008
Detection of HSV-1 variants highly resistant to the helicase–primase inhibitor BAY 57-1293 at high frequency in 2 of 10 recent clinical isolates of HSV-1
S Biswas, C Smith, HJ Field
Journal of antimicrobial chemotherapy 60 (2), 274-279, 2007
432007
High Frequency of Spontaneous Helicaseprimase Inhibitor (BAY 57–1293) Drug-Resistant Variants in Certain Laboratory Isolates of HSV-1
S Biswas, M Swift, HJ Field
Antiviral Chemistry and Chemotherapy 18 (1), 13-23, 2007
432007
Archived dengue serum samples produced false-positive results in SARS-CoV-2 lateral flow-based rapid antibody tests
H Nath, A Mallick, S Roy, S Sukla, K Basu, A De, S Biswas
Journal of Medical Microbiology 70 (6), 001369, 2021
412021
Comparative genomics of serotype Asia 1 foot-and-mouth disease virus isolates from India sampled over the last two decades
JK Mohapatra, A Sanyal, D Hemadri, C Tosh, S Biswas, NJ Knowles, ...
Virus research 136 (1-2), 16-29, 2008
412008
Mismatch primer-based PCR reveals that helicase–primase inhibitor resistance mutations pre-exist in herpes simplex virus type 1 clinical isolates and are not induced during …
S Sukla, S Biswas, A Birkmann, P Lischka, H Zimmermann, HJ Field
Journal of antimicrobial chemotherapy 65 (7), 1347-1352, 2010
402010
Single amino acid substitutions in the HSV-1 helicase protein that confer resistance to the helicase-primase inhibitor BAY 57-1293 are associated with increased or decreased …
S Biswas, L Jennens, HJ Field
Archives of virology 152, 1489-1500, 2007
392007
A mutation in helicase motif IV of herpes simplex virus type 1 UL5 that results in reduced growth in vitro and lower virulence in a murine infection model is related to …
S Biswas, RN Miguel, S Sukla, HJ Field
Journal of general virology 90 (8), 1937-1942, 2009
312009
Mutations close to functional motif IV in HSV-1 UL5 helicase that confer resistance to HSV helicase–primase inhibitors, variously affect virus growth rate and pathogenicity
S Biswas, LS Tiley, H Zimmermann, A Birkmann, HJ Field
Antiviral research 80 (1), 81-85, 2008
292008
Dengue antibodies can cross-react with SARS-CoV-2 and vice versa-Antibody detection kits can give false-positive results for both viruses in regions where both …
H Nath, A Mallick, S Roy, S Sukla, K Basu, A De, S Biswas
MedRxiv, 2020.07. 03.20145797, 2020
262020
Leptomonas seymouri narna-like virus 1 and not leishmaniaviruses detected in kala-azar samples from India
S Sukla, S Roy, S Sundar, S Biswas
Archives of Virology (Online text-only view available under Springer Nature …, 2017
242017
Effects of therapy using a helicase–primase inhibitor (HPI) in mice infected with deliberate mixtures of wild-type HSV-1 and an HPI-resistant UL5 mutant
S Sukla, S Biswas, A Birkmann, P Lischka, H Ruebsamen-Schaeff, ...
Antiviral research 87 (1), 67-73, 2010
232010
The system can't perform the operation now. Try again later.
Articles 1–20